论文部分内容阅读
目的:评价依托考昔与重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白注射剂(益赛普)联用患者难治性强直性脊柱炎(AS)的疗效与安全性。方法:选取2012年1月—2015年12月间收治的AS患者66例,采用随机数字表法将其分为对照组33例和治疗组33例;对照组患者给予益赛治疗,治疗组在对照组治疗基础上加用依托考昔治疗;治疗后第0、2、6、12周4个时间点评价两组患者临床疗效的评分值、及实验室检查项目测得值的变化情况和不良反应的发生率。结果:两组患者巴斯强直性脊柱炎病情活动指数、活动指数(BASDAI)、总评分值、脊柱痛和超敏C-反应蛋白(Hs-CRP)与治疗后第2、6、12周时均较同组治疗前有显著下降(P<0.05),但第6、12周时均低于治疗前(P<0.05);治疗2周治疗组患者各项指标均低于对照组及同组治疗前(P<0.05)。结论:采用依托考昔与益赛普治疗难治性AS患者起效较快,疗效较确切,安全性较好。
OBJECTIVE: To evaluate the efficacy and safety of ethacryxel combined with recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein injection (Isphaset) in patients with refractory ankylosing spondylitis (AS). Methods: Sixty-six patients with AS who were admitted from January 2012 to December 2015 were divided into control group (33 cases) and treatment group (33 cases) by random number table. Patients in the control group The control group was treated with ethafozol, and the scores of clinical curative effect in the two groups at 0, 2, 6, 12 weeks after treatment were evaluated, and the changes of the measured value of the laboratory test items and the unhealthy The incidence of reaction. Results: The activity index, activity index (BASDAI), total score, spinal pain and Hs-CRP in two groups of patients with ankylosing spondylitis were significantly lower than those in the two groups (P <0.05), but lower than before treatment (P <0.05) at the 6th and 12th week in treatment group. The indexes in the two weeks treatment group were lower than those in the control group and before treatment (P <0.05) <0.05). Conclusion: The treatment of patients with refractory AS using ethacryb and etanercept has faster onset, more exact effect and better safety.